Immatics Presents Clinical Activity of IMA402 and IMA203CD8 at ESMO 2026
Immatics reported positive clinical data for its PRAME-targeting therapies, IMA402 and IMA203CD8, during oral presentations at the 2026 ESMO Annual Meeting.
Stocks · News reference
Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Stifel analyst Laura Prendergast initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $15.
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.